SynthesisFrontiers in oncology2026
Immunotherapy plus targeted therapy for recurrent or metastatic head and neck squamous cell carcinoma: an updated meta-analysis and subgroup analysis by target mechanism.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) is an aggressive malignancy with dismal outcomes for patients with recurrent or metastatic (R/M) disease. Although immune checkpoint inhibitors (ICIs) have reshaped the treatment paradigm for R/M HNSCC, the efficacy of monotherapy remains limited. This meta-analysis was performed to comprehensively evaluate the efficacy and safety of immunotherapy combined with targeted therapy for R/M HNSCC and to clarify sources of between-study heterogeneity. Methods: We systematically searched PubMed, Embase, the Cochrane Library, and Web of Science from inception to May 1, 2026. Eligible studies enrolled patients with histologically confirmed R/M HNSCC receiving immunotherapy combined with targeted therapy and reported predefined efficacy or safety endpoints. Pooled analyses were conducted using Review Manager 5.4 to estimate rates of complete response (CR), partial response (PR), stable disease (SD), objective response rate (ORR), disease control rate (DCR), median progression-free survival (PFS), median overall survival (OS), and grade ≥3 treatment-related adverse events (TRAEs). Subgroup analyses stratified by targeted therapy mechanism were performed to explore heterogeneity. Results: A total of 22 studies comprising 1118 patients were included. Pooled estimates were as follows: CR rate 0.08 (95% CI: 0.05-0.10), PR rate 0.35 (95% CI: 0.27-0.42), ORR 0.41 (95% CI: 0.32-0.49), SD rate 0.26 (95% CI: 0.22-0.30), DCR 0.75 (95% CI: 0.66-0.83), median PFS 6.9 months, median OS 14.8 months, and grade ≥3 TRAEs rate 0.37 (95% CI: 0.24-0.50). Significant heterogeneity was detected across most endpoints and could not be alleviated by sensitivity analysis. Subgroup analyses demonstrated that anti-EGFR combinations achieved the highest ORR and DCR, whereas novel targeted combinations exhibited a more favorable safety profile. Conclusions: Immunotherapy combined with targeted therapy yields promising efficacy and manageable toxicity in patients with R/M HNSCC. The type of targeted agent represents a major source of heterogeneity. Anti-EGFR plus immunotherapy regimens show robust antitumor activity, while novel targeted combinations exhibit better tolerability. These findings support mechanism-based individualized combination strategies for R/M HNSCC in clinical practice. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251050561.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.